Autolus Therapeutics PLC ADR AUTL
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if AUTL is a good fit for your portfolio.
News
-
Abstract for longer-term follow-up and additional data analysis of Pivotal Phase 2 FELIX study of obe-cel for adult r/r B-ALL selected for an oral presentation at ASCO
-
Autolus Therapeutics to Report First Quarter 2024 Financial Results and Host Conference Call on May 14, 2024
-
Autolus Therapeutics announces acceptance of Marketing Authorization Application (MAA) by the European Medicines Agency (EMA) for obecabtagene autoleucel (obe-cel) for Patients with Relapsed/refractory (r/r) Adult B-Cell Acute Lymphoblastic Leukemia (B-ALL)
-
Autolus Therapeutics Announces Changes to its Board of Directors
-
Autolus Therapeutics Reports Full Year 2023 Financial Results and Business Updates
-
Autolus Therapeutics receives Medicines and Healthcare products Regulatory Agency (MHRA) certification for Nucleus commercial manufacturing site
-
Autolus Therapeutics announces publication in Blood Cancer Journal
-
Autolus Therapeutics to Report Full Year 2023 Financial Results and Business Updates on March 14, 2024
Trading Information
- Previous Close Price
- $4.21
- Day Range
- $3.96–4.29
- 52-Week Range
- $1.61–7.45
- Bid/Ask
- $3.90 / $4.09
- Market Cap
- $1.08 Bil
- Volume/Avg
- 3.9 Mil / 1.6 Mil
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 458.92
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- —
- Total Number of Employees
- 463
- Website
- https://www.autolus.com
Valuation
|
Metric
|
AUTL
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 7.00 |
Price/Sales | 458.92 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
AUTL
|
|---|---|
Quick Ratio | 5.90 |
Current Ratio | 6.15 |
Interest Coverage | −3.92 |
Quick Ratio
AUTL
Profitability
|
Metric
|
AUTL
|
|---|---|
Return on Assets (Normalized) | −45.95% |
Return on Equity (Normalized) | −92.33% |
Return on Invested Capital (Normalized) | −65.28% |
Return on Assets
AUTL
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Qxrglvgbs | Ntn | $562.4 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Wlqhqdyn | Qvynpvf | $103.6 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Bdxzpfyt | Kkxfvw | $99.5 Bil | |
MRNA
| Moderna Inc | Fcgtypdy | Cqcgb | $38.8 Bil | |
ARGX
| argenx SE ADR | Lzgdjmrn | Prrw | $22.3 Bil | |
BNTX
| BioNTech SE ADR | Gykdqyg | Qjlq | $21.2 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Fdpffbd | Xzmcsn | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Dhphsgns | Vqkppd | $17.3 Bil | |
RPRX
| Royalty Pharma PLC Class A | Gcyyqbrlfn | Jzgcgn | $12.5 Bil | |
INCY
| Incyte Corp | Chpwywz | Gfqrcj | $11.6 Bil |